Identification and Management of Late Toxicities After Radiation Therapy for Vulvar Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40562189.
- Also identified by DOI 10.1016/j.prro.2025.05.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Vulvar cancer is a rare malignancy, with an estimated 6.900 cases diagnosed in 2024, though incidence has been rising in recent years. Radiation plays a critical role in definitive and adjuvant management, however late toxicities including pelvic insufficiency fractures (PIFs), anal/fecal incontinence, sexual dysfunction, cutaneous and sub-cutaneous fibrosis, and lymphedema may significantly impact quality of life in long-term survivors. This article will describe the most commonly encountered late radiation-induced toxicities seen in the management of vulvar cancers and provide practical guidance regarding work-up, and evidence-based management.
Medical subject headings
- Vulvar Neoplasms
- Radiation Injuries
- Radiotherapy